Brookline Cap M Weighs in on iBio’s Q3 Earnings (NYSE:IBIO)

iBio, Inc. (NYSE:IBIO) – Stock analysts at Brookline Cap M raised their Q3 2026 earnings estimates for shares of iBio in a report issued on Wednesday, February 11th. Brookline Cap M analyst K. Dolliver now anticipates that the company will post earnings of ($0.07) per share for the quarter, up from their previous forecast of ($0.08). The consensus estimate for iBio’s current full-year earnings is ($1.74) per share. Brookline Cap M also issued estimates for iBio’s Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.34) EPS, Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.32) EPS.

A number of other research analysts have also weighed in on the company. Oppenheimer restated an “outperform” rating on shares of iBio in a report on Wednesday, October 29th. Chardan Capital reissued a “buy” rating and issued a $5.00 price target on shares of iBio in a research report on Thursday. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, iBio has an average rating of “Buy” and a consensus price target of $4.00.

iBio Stock Performance

Shares of IBIO stock opened at $2.22 on Monday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.05. The firm has a fifty day simple moving average of $2.15 and a two-hundred day simple moving average of $1.38. iBio has a 12 month low of $0.56 and a 12 month high of $6.89. The firm has a market capitalization of $76.69 million, a PE ratio of -2.22 and a beta of 1.26.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IBIO. Affinity Asset Advisors LLC purchased a new position in shares of iBio in the fourth quarter valued at $3,970,000. Ameriprise Financial Inc. purchased a new stake in iBio during the 3rd quarter worth about $399,000. Renaissance Technologies LLC bought a new position in iBio in the 4th quarter worth about $682,000. Monashee Investment Management LLC purchased a new position in iBio during the 4th quarter valued at about $530,000. Finally, Hudson Bay Capital Management LP purchased a new position in iBio during the 4th quarter valued at about $467,000. Institutional investors own 7.90% of the company’s stock.

About iBio

iBio, Inc (NYSE: IBIO) is a biotechnology company that develops and manufactures plant-based biologics, including vaccines and therapeutic proteins. Leveraging proprietary technology derived from Nicotiana benthamiana, a relative of tobacco, iBio applies a molecular farming approach to produce complex proteins more rapidly and with greater scalability than traditional cell-culture methods. The company’s core expertise lies in its ability to design, express and purify recombinant proteins for both research and commercial applications.

Central to iBio’s operations is the iBio CDM™ (cGMP-Direct Manufacture) platform, an integrated system that enables end-to-end development and production of biologics.